Gill, Adrian L.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 415

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 369

Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers

Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 343

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 264

Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers

Jiang, L., Menard, M., Weller, C., Wang, Z., Burnett, L., Aronchik, I., Steele, S., Flagella, M., Zhao, R., Evans, J. W. W., et al. (2023) · Cancer Research

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 76

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry

PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling

Cited by 72

Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers

Nichols, R. J., Yang, Y. C., Cregg, J., Schulze, C. J., Wang, Z., Dua, R., Jiang, J., Garrenton, L. S., Nasholm, N., Bermingham, A., et al. (2022) · Cancer Research

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 37

Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models

Knox, J. E., Jiang, J., Burnett, G. L., Liu, Y., Weller, C. E., Wang, Z., McDowell, L., Steele, S. L., Chin, S., Chou, K. J., et al. (2022) · Cancer Research

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 34

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Koltun, E. S., Rice, M. A., Gustafson, W. C., Wilds, D., Jiang, J., Lee, B. J., Wang, Z., Chang, S., Flagella, M., Mu, Y., et al. (2022) · Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 34

Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

Koltun, E., Cregg, J., Rice, M. A., Whalen, D. M., Freilich, R., Jiang, J., Hansen, R., Bermingham, A., Knox, J. E., Dinglasan, J., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 33

Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.

Gustafson, W. C., Wildes, D., Rice, M. A., Lee, B. J., Jiang, J., Wang, Z., Chang, S., Flagella, M., Mu, Y., Dinglasan, N., et al. (2022) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingPancreatic and Hepatic Oncology Research

Cited by 28

Abstract 1261: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition

Nichols, R. J., Cregg, J., Schulze, C. J., Wang, Z., Yang, K., Jiang, J., Whalen, D. M., Hansen, R., Garrenton, L. S., Bermingham, A., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 14